Evidence-informed pharmacology review updated 10 November 2026. Educational material, not a substitute for institutional protocols or individual clinical care.
Overview
Local anesthetics (LAs) reversibly block nerve conduction, enabling infiltration, topical anesthesia, peripheral nerve blocks and neuraxial techniques without necessarily altering consciousness. Safe use requires knowledge of agent potency, concentration, total administered dose, injection site, patient risk factors and local anesthetic systemic toxicity (LAST) [1,2].
Classification and pharmacodynamics
- Amino esters: procaine, chloroprocaine, tetracaine and benzocaine contain an ester linkage, which is not an ether bond; many are hydrolyzed by plasma esterases, though clinical duration varies greatly by agent.
- Amino amides: lidocaine, bupivacaine, ropivacaine, mepivacaine and prilocaine contain an amide linkage and generally undergo hepatic metabolism.
LAs bind voltage-gated sodium channels preferentially in open or inactivated states, producing use-dependent conduction block. Their pKa affects onset by influencing nonionized fraction; lipid solubility and protein binding contribute to potency and duration. Ester membership does not guarantee rapid onset or short action, nor does amide membership imply low systemic toxicity [1].
Pharmacokinetics and duration
Systemic absorption depends on site vascularity, total dose, vasoconstrictor coadministration and formulation. Epinephrine may prolong some blocks by reducing local absorption and can serve as a marker of intravascular injection, but it does not eliminate LAST risk. Hepatic dysfunction, low cardiac output, advanced age and pregnancy can alter clearance or susceptibility. Bupivacaine carries particular cardiotoxicity risk relative to some alternatives, so agent-specific limits are essential [1].
Clinical uses and special effects
Lidocaine is common for infiltration, nerve block and topical applications; bupivacaine and ropivacaine are used for longer-duration regional analgesia. Prilocaine and benzocaine can produce methemoglobinemia, especially in susceptible patients or after excessive topical exposure. Intrathecal formulations must be specifically suitable for neuraxial use; medication-error safeguards are essential [1].
Recognizing local anesthetic systemic toxicity
LAST may cause perioral numbness, metallic taste, tinnitus, agitation, seizures, arrhythmia or cardiovascular collapse; atypical presentations can occur without classic early symptoms. Stop injecting, call for help, secure airway and oxygenation, treat seizures and arrange resuscitation with 20% IV lipid emulsion according to the current ASRA LAST checklist. The ASRA protocol differs from standard ACLS drug choices and doses; do not manage it as ordinary cardiac arrest without adapting the algorithm [2].
Prevention and follow-up
Use the lowest appropriate dose, aspirate and inject incrementally when relevant, use ultrasound-guided techniques where appropriate, maintain monitoring and ready access to a LAST kit. Doses and precautions are drug-, formulation- and patient-specific; a single universal maximum is unsafe to teach [2].
References
- Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
- Neal JM, Neal EJ, Weinberg GL. American Society of Regional Anesthesia and Pain Medicine local anesthetic systemic toxicity checklist: 2020 version. Reg Anesth Pain Med. 2021;46:81–82. doi:10.1136/rapm-2020-101986. Available from: https://asra.com/news-publications/asra-updates/blog-landing/guidelines/2020/11/01/checklist-for-treatment-of-local-anesthetic-systemic-toxicity
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.